This is primarily due to the high prevalence of such mutations among NSCLC patients and their crucial role in predicting therapeutic responses to EGFR-specific tyrosine kinase inhibitors (TKIs) (Dang et al., 2020; Giulio et al., 2006; Lindeman et al., 2018). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.